The effectiveness of the use of synbiotics in the complex therapy of acute intestinal infections in children

Abstract

Relevance. Acute intestinal infections in children retain a high value in the structure of child morbidity and mortality, which necessitates the search for means and methods for their active treatment and improvement of prognosis.
 Aim: to determine the effectiveness of the use of synbiotics in the complex therapy of acute intestinal infections in children at the outpatient stage.
 Materials and methods. Fifty 6–17 years children with mild or moderate acute intestinal infections were examined. The patients were divided into the main group (30 children) and the control group (20 children), the groups were comparable. Patients from the main group, along with pathogenetic therapy, received a combination of Lacticaseibacillus paracasei DG I-1572 DSM 34154 
 (L. casei DG) and fructooligosaccharides (FOS), and children from the control group received only pathogenetic and symptomatic treatment. Clinical symptoms were evaluated over following up included temperature, frequency and, nature of stool, presence and severity of dyspeptic manifestations, nausea, frequency of vomiting, presence and severity of abdominal pain syndrome. Statistical data processing was carried out using statistical analysis Statistica v. 13.0 (StatSoft Inc., USA).
 Results. The combined use of L. casei DG and FOS in the pathogenetic therapy of acute intestinal infections reduces the time of relief of clinical manifestations. The severity of abdominal pain syndrome regresses significantly faster when using this synbiotic. Norma­lization of the frequency and nature of stool occurs significantly faster with the simultaneous appointment of pathogenetic therapy and the synbiotic. The combination of L. casei DG and FOS has demonstrated a high safety profile, side effects have not been reported.
 Conclusion. It is advisable to prescribe the combination of L. casei DG and FOS from the first day of acute intestinal infections alongside with pathogenetic and symptomatic therapy to achieve a clinical effect more quickly.